AngioDynamics, Inc. - Common Stock (ANGO)

AngioDynamics (ANGO) Q1 2026 Earnings Transcript

AngioDynamics (ANGO) Q3 2025 Earnings Transcript

AngioDynamics (ANGO) Q1 2025 Earnings Transcript

AngioDynamics (ANGO) Q2 2026 Earnings Transcript

An unexpected departure at the top is overshadowing a positive quarterly update for AngioDynamics.

Acuitas Dumps Entire Stake in SBH Valued at $2.7 Million

Is Mechanics Bancorp Stock a Buy After Investment Firm Acuitas Initiated a Large Position in the Bank?

AngioDynamics (ANGO) exceeds expectations, raises guidance for fiscal 2026 with positive cash flow expected.

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 0.2% on Thursday. The Dow traded up 0.20% to 46,532.02 while the NASDAQ rose 0.34% to 22,833.17. The S&P 500 also rose, gaining, 0.07% to 6,715.87.

Even 37 years after its founding, AngioDynamics still can't earn a profit.

Shares of AngioDynamics, Inc. (NASDAQ: ANGO) are up Thursday after the biotechnology company raised guidance for four key financial metrics and shared positive sales performance for this past quarter.

AngioDynamics (ANGO) beat Q1 FY2026 earnings and revenue estimates, driven by strong Med Tech growth. The company also raised its full-year financial outlook.

U.S. stock futures were fluctuating on Thursday following Wednesday's record advances. Futures of major benchmark indices were mixed.

CNN Business Fear & Greed Index at 52.3, remaining in Neutral zone. Stocks close higher despite economic headwinds, with record S&P 500 level.

US stock futures mixed, with attention on earnings reports from companies like AngioDynamics, Grindr, and Entero Therapeutics.

AngioDynamics' big Q4 earnings beat wasn't as impressive as it first seemed.

AngioDynamics expects a $4 million-$6 million impact from tariffs. Still, it's "profitable," CEO Jim Clemmer says.